KRAS and cancer: Attempts to block factors involved in MAP kinase signaling (such as MEK and Raf) or binding partners to KRAS have shown some clinical promise in specific cancer types but have presented challenges with toxicity and eventual treatment resistance even in combination with other treatment options [5–7].